Programmed cell death is an intrinsic feature of MDS progenitors, predominantly found in the cluster-forming cells

被引:13
作者
Span, LFR
Vierwinden, G
Pennings, AH
Boezeman, JBM
Raymakers, RAP
de Witte, T
机构
[1] Univ Nijmegen, Med Ctr, Dept Hematol, NL-6500 HB Nijmegen, Netherlands
[2] Univ Nijmegen, Med Ctr, Cent Hematol Lab, NL-6500 HB Nijmegen, Netherlands
关键词
D O I
10.1016/j.exphem.2004.12.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Bone marrows (BM) of myelodysplastic syndrome (NIDS) patients show increased proliferation and premature programmed cell death (PCD) in vivo as well as in vitro. We explored the proliferative capacity and apoptotic propensity of CD34(+) progenitor cells of MDS patients excluding accessory cell interference. Materials and Methods. CD34(+)/CD3(-)/CD19(-) cells of 5 NIDS patients and 5 normal BM were sorted as single cells into single wells and were cultured in liquid medium. Wells were evaluated on days 4, 7, 10, and 14. PCD was determined by staining with annexin V-FITC. Growth rate and cell doubling time (Td) were calculated for each colony-forming cell. Results. Normal BM CD34+ cells formed clusters and colonies and both showed increasing PCD in time, although within colonies the degree of apoptosis was twice as high (about 25%) as compared with clusters at all time points. In NIDS increased cluster formation was observed at all evaluation points when compared to normal BM, whereas the number of colonies was markedly reduced (1/7 of normal). These colonies were also smaller, usually smaller than 100 cells. Significantly enhanced levels of PCD of clusters (53-79 %) in combination with longer cell doubling times explain this slower formation of smaller colonies. Surprisingly, these colonies showed considerably lower levels of PCD (7-32%) as compared to normal (1-48%, median values). C Conclusions. In the absence of stromal influences and accessory cells, this study in NIDS patients showed intrinsically enhanced proliferation and apoptosis of cluster-forming cells, as the opposite was true for colony-forming cells. C 2005 International Society for Experimental Hematology. Published by Elsevier Inc.
引用
收藏
页码:435 / 442
页数:8
相关论文
共 39 条
[1]   Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation in vitro [J].
Aizawa, S ;
Nakano, M ;
Iwase, O ;
Yaguchi, M ;
Hiramoto, M ;
Hoshi, H ;
Nabeshima, R ;
Shima, D ;
Handa, H ;
Toyama, K .
LEUKEMIA RESEARCH, 1999, 23 (03) :239-246
[2]  
Boezeman J, 1997, CYTOMETRY, V28, P305
[3]   Fas/Apo-1(CD95) expression and apoptosis in patients with myelodysplastic syndromes [J].
Bouscary, D ;
DeVos, J ;
Guesnu, M ;
Jondeau, K ;
Viguier, F ;
Melle, J ;
Picard, F ;
Dreyfus, F ;
FontenayRoupie, M .
LEUKEMIA, 1997, 11 (06) :839-845
[4]   Activity of the caspase-3/CPP32 enzyme is increased in "early stage" myelodysplastic syndromes with excessive apoptosis, but caspase inhibition does not enhance colony formation in vitro [J].
Bouscary, D ;
Chen, YL ;
Guesnu, M ;
Picard, F ;
Viguier, F ;
Lacombe, C ;
Dreyfus, F ;
Fontenay-Roupie, M .
EXPERIMENTAL HEMATOLOGY, 2000, 28 (07) :784-791
[5]   Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities [J].
Chen, GB ;
Zeng, WH ;
Miyazato, A ;
Billings, E ;
Maciejewski, JP ;
Kajigaya, S ;
Sloand, EM ;
Young, NS .
BLOOD, 2004, 104 (13) :4210-4218
[6]   The role of mitochondrial-mediated apoptosis in a myelodysplastic syndrome secondary to congenital deletion of the short arm of chromosome 4 [J].
Dror, Y .
EXPERIMENTAL HEMATOLOGY, 2003, 31 (03) :211-217
[7]   Hematopoietic progenitor cells from patients with myelodysplastic syndromes:: in vitro colony growth and long-term proliferation [J].
Flores-Figueroa, E ;
Gutiérrez-Espindola, G ;
Guerrero-Rivera, S ;
Pizzuto-Chavez, J ;
Mayani, H .
LEUKEMIA RESEARCH, 1999, 23 (04) :385-394
[8]   A role for tumour necrosis factor-α, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome [J].
Gersuk, GR ;
Beckham, C ;
Loken, MR ;
Kiener, P ;
Anderson, JE ;
Farrand, A ;
Troutt, AB ;
Ledbetter, JA ;
Deeg, HJ .
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 103 (01) :176-188
[9]   International scoring system for evaluating prognosis in myelodysplastic syndromes [J].
Greenberg, P ;
Cox, C ;
LeBeau, MM ;
Fenaux, P ;
Morel, P ;
Sanz, G ;
Sanz, M ;
Vallespi, T ;
Hamblin, T ;
Oscier, D ;
Ohyashiki, K ;
Toyama, K ;
Aul, C ;
Mufti, G ;
Bennett, J .
BLOOD, 1997, 89 (06) :2079-2088
[10]   Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival [J].
Gupta, P ;
Niehans, GA ;
LeRoy, SC ;
Gupta, K ;
Morrison, VA ;
Schultz, C ;
Knapp, DJ ;
Kratzke, RA .
LEUKEMIA, 1999, 13 (01) :44-53